#4 - Danaher (NYSE:DHR)
Danaher (NYSE:DHR) stock is down 11.9% from its 52-week high. However, the stock has been bouncing higher since reporting positive earnings in late January. Analysts have been lowering their price targets, but DHR stock still has a consensus price target of $337.77 which would take it past its previous 52-week high.
Danaher has grown its earnings per share (EPS) by an average of 36% per year over the last three years. And the company has always made a point of prioritizing cash flow. That was evident in the company’s last earnings report. The company over $7 billion of free cash flow in 2021. That was a 30% year-over-year increase.
Of all the company’s on this list, Danaher has the lowest Net Impact Ratio score coming in at 47.4%. However, the company’s contribution to improving patient outcomes with its medical devices and diagnostic testing makes the company a solid choice for investors looking for ESG stocks to buy.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
More- Current Price
- $212.42
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 15 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $278.00 (30.9% Upside)
